SPY
772.75
−0.68%
QQQ
736.48
−0.95%
BTC/USD
81,758.23
−1.62%
DIA
515.85
−0.07%
GLD
375.95
−1.50%
TLT
78.35
−0.03%
US
Sign in
Register
My Account
Benzinga
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
IN8bio Inc
INAB
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.17
-0.01
-0.85%
Last update: Oct 14, 10:33 AM
$1.17
-0.01
-0.85%
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Compare
Stock Report
Privacy Manager
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
IN8bio Financials
IN8bio (INAB) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
IN8bio Q2 EPS $(0.25) Beats $(0.37) Estimate
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.37) by 32.43 percent. This is a 79.84 percent increase over losses of $(1.24) per share from the same
Benzinga Newsdesk
PRO
IN8bio Q1 EPS $(0.26) Beats $(0.69) Estimate
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.69) by 62.32 percent. This is a 87.96 percent increase over losses of $(2.16) per share from the same
Benzinga Newsdesk
PRO
IN8bio Q4 EPS $(0.26) Beats $(0.51) Estimate
Benzinga Newsdesk
PRO
IN8bio Q3 EPS $(0.85) Beats $(1.25) Estimate
Benzinga Newsdesk
PRO
IN8bio Q2 EPS $(1.24) Beats $(1.70) Estimate
IN8bio (NASDAQ:INAB) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.70) by 27.06 percent. This is a 78.25 percent increase over losses of $(5.70) per share from the same
Benzinga Newsdesk
PRO
IN8bio Q1 EPS $(0.07), Inline
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 65 percent increase over losses of $(0.20) per share from the same period last year.
Benzinga Newsdesk
